MX2022008654A - Formulaciones para productos terapeuticos proteicos. - Google Patents
Formulaciones para productos terapeuticos proteicos.Info
- Publication number
- MX2022008654A MX2022008654A MX2022008654A MX2022008654A MX2022008654A MX 2022008654 A MX2022008654 A MX 2022008654A MX 2022008654 A MX2022008654 A MX 2022008654A MX 2022008654 A MX2022008654 A MX 2022008654A MX 2022008654 A MX2022008654 A MX 2022008654A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- formulations
- protein therapeutics
- protein
- multispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En el presente documento se describen composiciones que comprenden productos terapéuticos proteicos, que incluyen proteínas de fusión y polipéptidos multiespecíficos, para administración intravenosa. Las composiciones pueden comprender, por ejemplo, una proteína multiespecífica, una solución amortiguadora, un excipiente y un tensioactivo. En algunas modalidades, las composiciones pueden comprender una proteína multiespecífica, una solución amortiguadora de succinato, sacarosa y polisorbato 80. También se proporcionan en este documento métodos clínicos, que incluyen regímenes de dosificación, para la administración de las composiciones a un sujeto que lo necesite.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062960562P | 2020-01-13 | 2020-01-13 | |
US202063121633P | 2020-12-04 | 2020-12-04 | |
PCT/US2021/013294 WO2021146328A1 (en) | 2020-01-13 | 2021-01-13 | Formulations for protein therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022008654A true MX2022008654A (es) | 2022-08-18 |
Family
ID=74592744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022008654A MX2022008654A (es) | 2020-01-13 | 2021-01-13 | Formulaciones para productos terapeuticos proteicos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230303720A1 (es) |
EP (1) | EP4090367A1 (es) |
JP (1) | JP2023512454A (es) |
KR (1) | KR20220127843A (es) |
CN (1) | CN115279406A (es) |
AU (1) | AU2021207470A1 (es) |
BR (1) | BR112022013725A2 (es) |
CA (1) | CA3164385A1 (es) |
IL (1) | IL294458A (es) |
MX (1) | MX2022008654A (es) |
WO (1) | WO2021146328A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
ATE455127T1 (de) | 2003-05-31 | 2010-01-15 | Micromet Ag | Humane anti-humane cd3-bindungsmoleküle |
EP1629012B1 (en) | 2003-05-31 | 2018-11-28 | Amgen Research (Munich) GmbH | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
KR20120125634A (ko) | 2003-10-16 | 2012-11-16 | 마이크로메트 에이지 | 다중특이적 탈면역화된 cd3-바인더 |
US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
US9889197B2 (en) | 2005-04-15 | 2018-02-13 | Macrogenics, Inc. | Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin |
KR101571027B1 (ko) | 2006-06-12 | 2015-11-23 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 효과기 기능을 갖는 단일쇄 다가 결합 단백질 |
WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
BRPI0914005A2 (pt) | 2008-07-02 | 2015-11-17 | Emergent Product Dev Seattle | proteínas antagonistas tnf-alfa de ligação a alvos múltiplos |
SI2356153T1 (sl) | 2008-10-01 | 2016-07-29 | Amgen Research (Munich) Gmbh | Bispecifično enoverižno protitelo, specifično za križane vrste |
DK2344540T3 (da) | 2008-10-02 | 2018-01-29 | Aptevo Res & Development Llc | Cd86-antagonist multimål bindingsproteiner |
EP3112382A1 (en) | 2009-12-29 | 2017-01-04 | Emergent Product Development Seattle, LLC | Heterodimer binding proteins and uses thereof |
US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
EP2714733B1 (en) | 2011-05-21 | 2019-01-23 | MacroGenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
RU2673153C2 (ru) | 2012-04-20 | 2018-11-22 | АПТЕВО РИСЁРЧ ЭНД ДИВЕЛОПМЕНТ ЭлЭлСи | Полипептиды, связывающиеся с cd3 |
WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
CA2986415A1 (en) | 2015-05-21 | 2016-11-24 | Alligator Bioscience Ab | Anti-cd137 antibodies |
CA2999138C (en) | 2015-09-21 | 2024-05-21 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
US11242400B2 (en) * | 2016-09-21 | 2022-02-08 | Aptevo Research And Development Llc | CD123 binding proteins and related compositions and methods |
WO2019050521A1 (en) * | 2017-09-07 | 2019-03-14 | Macrogenics, Inc. | DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES |
-
2021
- 2021-01-13 US US17/802,920 patent/US20230303720A1/en active Pending
- 2021-01-13 BR BR112022013725A patent/BR112022013725A2/pt unknown
- 2021-01-13 MX MX2022008654A patent/MX2022008654A/es unknown
- 2021-01-13 CN CN202180020514.1A patent/CN115279406A/zh active Pending
- 2021-01-13 KR KR1020227026642A patent/KR20220127843A/ko unknown
- 2021-01-13 CA CA3164385A patent/CA3164385A1/en active Pending
- 2021-01-13 IL IL294458A patent/IL294458A/en unknown
- 2021-01-13 WO PCT/US2021/013294 patent/WO2021146328A1/en unknown
- 2021-01-13 AU AU2021207470A patent/AU2021207470A1/en active Pending
- 2021-01-13 EP EP21704990.7A patent/EP4090367A1/en active Pending
- 2021-01-13 JP JP2022542670A patent/JP2023512454A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023512454A (ja) | 2023-03-27 |
AU2021207470A1 (en) | 2022-07-07 |
EP4090367A1 (en) | 2022-11-23 |
KR20220127843A (ko) | 2022-09-20 |
US20230303720A1 (en) | 2023-09-28 |
IL294458A (en) | 2022-09-01 |
BR112022013725A2 (pt) | 2022-10-11 |
CN115279406A (zh) | 2022-11-01 |
CA3164385A1 (en) | 2021-07-22 |
WO2021146328A1 (en) | 2021-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gunnarsson et al. | Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNγ-transduced tumor cell immunotherapy of experimental glioma | |
CN1993139B (zh) | 稳定的干扰素液体制剂 | |
MX2020006822A (es) | Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa. | |
CY1123307T1 (el) | Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν | |
AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
NZ592918A (en) | Antibody formulation comprising an IL-1beta antibody and a buffer | |
CY1114244T1 (el) | Σκευασματα ανταγωνιστη vegf καταλληλα για ενδοϋαλωδη χορηγηση | |
AR079836A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r) | |
AR036852A1 (es) | Preconcentrado de una microemulsion de analogos de ciclosporina, su metodo de preparacion y metodos para producir inmunosupresion | |
MY197773A (en) | Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody | |
MX2021005018A (es) | Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma. | |
Lubenau et al. | Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen®: single-blind, randomized, crossover trial | |
US20140044727A1 (en) | Formulations with reduced viscosity | |
MX2013012545A (es) | Preparacion liofilizada de dipeptidos citotoxicos. | |
HUE034398T2 (en) | Liquid preparations for sustained G-CSF conjugate | |
CN107249622A (zh) | 包含纤溶酶原的药物组合物和其用途 | |
MX2022008654A (es) | Formulaciones para productos terapeuticos proteicos. | |
MX2020005170A (es) | Formulaciones de proteinas de fusion vegfr-fc. | |
Deng et al. | PEGylation alleviates the non-specific toxicities of Alpha-Momorcharin and preserves its antitumor efficacy in vivo | |
DE23189888T1 (de) | Flüssige pharmazeutische zusammensetzung von adalimumab | |
BRPI1101565A2 (pt) | novo conjugado de polietileno glicol estável de interferon alfa, representado por um isÈmero posicional | |
HUE035619T2 (en) | Stabilization of polypeptides | |
EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
ZA202207051B (en) | Programmed cell death receptor 1 antibody formulation and use thereof | |
MX2022007546A (es) | Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. |